Description
P.17 Complete responses of the TEMPI syndrome to bortezomib
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: P.17 Complete responses of the TEMPI syndrome to bortezomib
€3.03
Related products
-
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
Article: Highlights in digestive oncology
€3.03 Add to cart -
Article: Calendar of events
€3.03 Add to cart -
Article: Highlights in genitourinary cancers
€3.03 Add to cart
Reviews
There are no reviews yet.